Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice

Cathleen Rich, Jason Link, Alex Zamora, Helle Jacobsen, Roberto Meza-Romero, Halina Offner, Richard Jones, Gregory G. Burrows, Lars Fugger, Arthur Vandenbark

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The use of HLA class II-transgenic (Tg) mice has facilitated identification of antigenic T cell epitopes that may contribute to inflammation in T cell-mediated diseases such as rheumatoid arthritis and multiple sclerosis (MS). In this study, we compared the encephalitogenic activity of three DR2-restricted myelin determinants [mouse (m) myelin oligodendrocyte glycoprotein (MOG)-35-55, human (h)MOG-35-55 and myelin basic protein (MBP)-87-99] in Tg mice expressing the MS-associated DR2 allele, DRB11501. We found that mMOG-35-55 peptide was strongly immunogenic and induced moderately severe chronic experimental autoimmune encephalomyelitis (EAE) with white matter lesions after a single injection in Freund's complete adjuvant followed by pertussis toxin. hMOG-35-55 peptide, which differs from mMOG-35-55 peptide by a proline for serine substitution at position 42, was also immunogenic, but not encephalitogenic, and was only partially cross-reactive with mMOG- 35-55. In contrast, MBP-87-99, which can induce EAE in double-Tg mice expressing both HLA-DR2 and a human MBP-specific TCR, was completely non-encephalitogenic in HLA- DR2-Tg mice lacking the human TCR transgene. These findings demonstrate potent encephalitogenic activity of the mMOG-35-55 peptide in association with HLA-DR2, thus providing a strong rationale for further study of hMOG-35-55 peptide as a potential pathogenic determinant in humans.

Original languageEnglish (US)
Pages (from-to)1251-1261
Number of pages11
JournalEuropean Journal of Immunology
Volume34
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

HLA-DR2 Antigen
Autoimmune Experimental Encephalomyelitis
Transgenic Mice
Peptides
Multiple Sclerosis
T-Lymphocyte Epitopes
Freund's Adjuvant
Pertussis Toxin
Myelin Sheath
Transgenes
Proline
Serine
Rheumatoid Arthritis
Alleles
myelin oligodendrocyte glycoprotein (35-55)
Inflammation
T-Lymphocytes
Injections

Keywords

  • CNS inflammation
  • Experimental autoimmune encephalomyelitis
  • HLA-DR2-transgenic mice
  • MOG peptide
  • T cell activation

ASJC Scopus subject areas

  • Immunology

Cite this

Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. / Rich, Cathleen; Link, Jason; Zamora, Alex; Jacobsen, Helle; Meza-Romero, Roberto; Offner, Halina; Jones, Richard; Burrows, Gregory G.; Fugger, Lars; Vandenbark, Arthur.

In: European Journal of Immunology, Vol. 34, No. 5, 05.2004, p. 1251-1261.

Research output: Contribution to journalArticle

Rich, Cathleen ; Link, Jason ; Zamora, Alex ; Jacobsen, Helle ; Meza-Romero, Roberto ; Offner, Halina ; Jones, Richard ; Burrows, Gregory G. ; Fugger, Lars ; Vandenbark, Arthur. / Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. In: European Journal of Immunology. 2004 ; Vol. 34, No. 5. pp. 1251-1261.
@article{3e0c7aa54f554de694577814a6a6be1c,
title = "Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice",
abstract = "The use of HLA class II-transgenic (Tg) mice has facilitated identification of antigenic T cell epitopes that may contribute to inflammation in T cell-mediated diseases such as rheumatoid arthritis and multiple sclerosis (MS). In this study, we compared the encephalitogenic activity of three DR2-restricted myelin determinants [mouse (m) myelin oligodendrocyte glycoprotein (MOG)-35-55, human (h)MOG-35-55 and myelin basic protein (MBP)-87-99] in Tg mice expressing the MS-associated DR2 allele, DRB11501. We found that mMOG-35-55 peptide was strongly immunogenic and induced moderately severe chronic experimental autoimmune encephalomyelitis (EAE) with white matter lesions after a single injection in Freund's complete adjuvant followed by pertussis toxin. hMOG-35-55 peptide, which differs from mMOG-35-55 peptide by a proline for serine substitution at position 42, was also immunogenic, but not encephalitogenic, and was only partially cross-reactive with mMOG- 35-55. In contrast, MBP-87-99, which can induce EAE in double-Tg mice expressing both HLA-DR2 and a human MBP-specific TCR, was completely non-encephalitogenic in HLA- DR2-Tg mice lacking the human TCR transgene. These findings demonstrate potent encephalitogenic activity of the mMOG-35-55 peptide in association with HLA-DR2, thus providing a strong rationale for further study of hMOG-35-55 peptide as a potential pathogenic determinant in humans.",
keywords = "CNS inflammation, Experimental autoimmune encephalomyelitis, HLA-DR2-transgenic mice, MOG peptide, T cell activation",
author = "Cathleen Rich and Jason Link and Alex Zamora and Helle Jacobsen and Roberto Meza-Romero and Halina Offner and Richard Jones and Burrows, {Gregory G.} and Lars Fugger and Arthur Vandenbark",
year = "2004",
month = "5",
doi = "10.1002/eji.200324354",
language = "English (US)",
volume = "34",
pages = "1251--1261",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "5",

}

TY - JOUR

T1 - Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice

AU - Rich, Cathleen

AU - Link, Jason

AU - Zamora, Alex

AU - Jacobsen, Helle

AU - Meza-Romero, Roberto

AU - Offner, Halina

AU - Jones, Richard

AU - Burrows, Gregory G.

AU - Fugger, Lars

AU - Vandenbark, Arthur

PY - 2004/5

Y1 - 2004/5

N2 - The use of HLA class II-transgenic (Tg) mice has facilitated identification of antigenic T cell epitopes that may contribute to inflammation in T cell-mediated diseases such as rheumatoid arthritis and multiple sclerosis (MS). In this study, we compared the encephalitogenic activity of three DR2-restricted myelin determinants [mouse (m) myelin oligodendrocyte glycoprotein (MOG)-35-55, human (h)MOG-35-55 and myelin basic protein (MBP)-87-99] in Tg mice expressing the MS-associated DR2 allele, DRB11501. We found that mMOG-35-55 peptide was strongly immunogenic and induced moderately severe chronic experimental autoimmune encephalomyelitis (EAE) with white matter lesions after a single injection in Freund's complete adjuvant followed by pertussis toxin. hMOG-35-55 peptide, which differs from mMOG-35-55 peptide by a proline for serine substitution at position 42, was also immunogenic, but not encephalitogenic, and was only partially cross-reactive with mMOG- 35-55. In contrast, MBP-87-99, which can induce EAE in double-Tg mice expressing both HLA-DR2 and a human MBP-specific TCR, was completely non-encephalitogenic in HLA- DR2-Tg mice lacking the human TCR transgene. These findings demonstrate potent encephalitogenic activity of the mMOG-35-55 peptide in association with HLA-DR2, thus providing a strong rationale for further study of hMOG-35-55 peptide as a potential pathogenic determinant in humans.

AB - The use of HLA class II-transgenic (Tg) mice has facilitated identification of antigenic T cell epitopes that may contribute to inflammation in T cell-mediated diseases such as rheumatoid arthritis and multiple sclerosis (MS). In this study, we compared the encephalitogenic activity of three DR2-restricted myelin determinants [mouse (m) myelin oligodendrocyte glycoprotein (MOG)-35-55, human (h)MOG-35-55 and myelin basic protein (MBP)-87-99] in Tg mice expressing the MS-associated DR2 allele, DRB11501. We found that mMOG-35-55 peptide was strongly immunogenic and induced moderately severe chronic experimental autoimmune encephalomyelitis (EAE) with white matter lesions after a single injection in Freund's complete adjuvant followed by pertussis toxin. hMOG-35-55 peptide, which differs from mMOG-35-55 peptide by a proline for serine substitution at position 42, was also immunogenic, but not encephalitogenic, and was only partially cross-reactive with mMOG- 35-55. In contrast, MBP-87-99, which can induce EAE in double-Tg mice expressing both HLA-DR2 and a human MBP-specific TCR, was completely non-encephalitogenic in HLA- DR2-Tg mice lacking the human TCR transgene. These findings demonstrate potent encephalitogenic activity of the mMOG-35-55 peptide in association with HLA-DR2, thus providing a strong rationale for further study of hMOG-35-55 peptide as a potential pathogenic determinant in humans.

KW - CNS inflammation

KW - Experimental autoimmune encephalomyelitis

KW - HLA-DR2-transgenic mice

KW - MOG peptide

KW - T cell activation

UR - http://www.scopus.com/inward/record.url?scp=4544353193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544353193&partnerID=8YFLogxK

U2 - 10.1002/eji.200324354

DO - 10.1002/eji.200324354

M3 - Article

C2 - 15114658

AN - SCOPUS:4544353193

VL - 34

SP - 1251

EP - 1261

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 5

ER -